In the method of percutaneous interventional therapy, the preferred regimen for ventricular septal defect (VSD) is the use of an occluder. However, most currently available occluders are made of nickel⁃titanium alloy materials, which remains permanently in the body after implantation. This may lead to complications such as chronic inflammation, arrhythmias, and cardiac perforation. In 2022, the world's first MemoSorb® degradable occluder was approved for clinical use. This device features self⁃degrading properties—once implanted at the defect site, it gradually breaks down into carbon dioxide, water, and lactic acid, all of which are harmless to the human body. This innovative occluder not only effectively avoids adverse events associated with traditional occluders (including nickel allergy) but also eliminates interference with subsequent interventional therapy, achieving the goal of "implant⁃free" interventional therapy. However, current degradable occluders have limited visibility via X⁃ray imaging, requiring reliance on auxiliary imaging systems and the operator's experience for precise positioning. Future improvements such as material engineering enhancements, structural optimization of the device, and standardized procedural protocols could further enhance the safety and therapeutic efficiency of degradable occluders.

无